CSRXP ANALYSIS FINDS BIG PHARMA’S DIRECT-TO-CONSUMER (DTC) ADVERTISING COSTS U.S. TAXPAYERS BILLIONS OF DOLLARS
Mar 18, 2025
Study Finds Reducing or Taxing Brand Name Drug Companies’ Nearly $14 Billion… Read More
© 2025 CSRXP- All Rights Reserved
Press Release
CSRXP APPLAUDS U.S. SENATE REINTRODUCTION OF BIPARTISAN, MARKET-BASED SOLUTIONS TO LOWER DRUG PRICES BY ADDRESSING BIG PHARMA’S PATENT ABUSE
Mar 14, 2025
Cracking Down on Anti-Competitive Tactics Like Patent-Thicketing and… Read More
ICYMI: CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Dec 17, 2024
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
CSRxP ANALYSIS FINDS PHARMACEUTICAL INDUSTRY’S PROFIT MARGINS TEN TIMES GREATER THAN OTHER SECTORS OF DRUG SUPPLY CHAIN
Nov 20, 2024
Study Finds Big Pharma’s Price-Gouging and Patent Abuse Playbook Fuels… Read More
CSRxP: SENATE JUDICIARY COMMITTEE SHOULD REJECT PHARMA-SUPPORTED POLICIES THAT WOULD UNDERMINE BIPARTISAN PROGRESS ON PATENT ABUSE
Sep 25, 2024
Lawmakers Should Remain Focused on Holding Big Pharma Accountable for… Read More
CSRxP ENCOURAGES HELP COMMITTEE TO ADVANCE BIPARTISAN SOLUTIONS TO PROMOTE GREATER COMPETITION IN THE PRESCRIPTION DRUG MARKET
Sep 24, 2024
Legislation Scheduled for Thursday Markup Would Encourage Adoption of… Read More
CSRxP: BIG PHARMA’S EGREGIOUS GLP-1 PRICES AND ANTI-COMPETITIVE TACTICS UNSUSTAINABLE FOR PATIENTS AND U.S. HEALTH CARE SYSTEM
Sep 24, 2024
HELP Committee Hearing an Opportunity to Highlight Staggering Cost… Read More
CSRxP JOINS FELLOW ADVOCATES FOR LOWER DRUG PRICES TO URGE HOUSE JUDICIARY COMMITTEE TO CRACK DOWN ON BIG PHARMA’S PATENT ABUSE
Sep 6, 2024
Letter Encourages Lawmakers to Advance Bipartisan Solutions to Hold Big Pharma… Read More
CSRxP Launches Seven-Figure Advertising Campaign to Hold Big Pharma Accountable for Egregious Drug Prices, Anti-Competitive Tactics and False Rhetoric
Sep 4, 2024
Campaign Will Add Support to Growing Bipartisan Momentum to Crack Down on Big… Read More
CSRXP: BIG PHARMA’S JANUARY PRICE HIKES CLIMB TO 775 AS PHARMACEUTICAL INDUSTRY DOUBLES DOWN ON BUSINESS-AS-USUAL APPROACH TO PRICE-GOUGING
Jan 18, 2024
Brand Name Drug Companies’ Price Increases in First Two Weeks of 2024… Read More
CSRXP: GSK’S FLOVENT SCHEME DESIGNED TO SIDESTEP ACCOUNTABILITY FOR EGREGIOUS PRICE HIKES
Jan 5, 2024
Big Pharma Giant Switches Popular Brand Name Inhaler to Authorized Generic to… Read More
CSRXP: BIG PHARMA RINGS IN 2024 WITH EGREGIOUS PRICE HIKES ON HUNDREDS OF BRAND NAME PRESCRIPTION DRUGS
Jan 2, 2024
Big Pharma Maintains Business-as-Usual Approach to Price-Gouging Americans to… Read More